Strategic Growth Biorasi is a mid-sized global CRO with a revenue range of 250-500 million, signaling solid capabilities and growth potential for expanding into larger biotech and biopharma sponsor portfolios. Focus sales on mid-sized companies seeking faster, flexible trial execution across dermatology, oncology, neurology, and nephrology.

Leadership Momentum Recent leadership changes including a new COO and board appointment indicate a strategy shift toward delivery excellence and organizational effectiveness. Opportunity to position services around improved program governance, metrics-driven performance, and scalable study execution.

Tech-Forward Edge Biorasi employs a diverse tech stack (iCIMS, SAP, Snowflake, NetSuite, Pardot, New Relic, Teams) and has recent AI-driven site selection partnerships. Venta points include offering integrated tech-enabled trial operations, data analytics, and AI-assisted feasibility to accelerate site activation and study delivery.

Strategic Partnerships Recent collaborations with Ryght AI for site optimization and a history of pharma partnerships (Alzamend Neuro, Citius Pharmaceuticals) show openness to innovative capabilities and outsourcing models. Target sponsors looking to augment feasibility, site selection, and rapid enrollment through advanced tools.

Client Success Signals Five FDA-approved trials in seven years and repeat business emphasize reliability and value. Target sponsors seeking proven performance, risk mitigation, and flexible modular CRO solutions with a track record of study rescues and biotech-focused strategies.